Neel Butala
Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transcatheter Aortic Valve Replacement | 17 | 2025 | 130 | 8.920 |
Why?
| | Aortic Valve Stenosis | 13 | 2025 | 229 | 6.970 |
Why?
| | Percutaneous Coronary Intervention | 22 | 2025 | 480 | 5.140 |
Why?
| | Embolic Protection Devices | 4 | 2024 | 12 | 2.520 |
Why?
| | Administrative Claims, Healthcare | 4 | 2025 | 26 | 1.990 |
Why?
| | Heart Valve Prosthesis Implantation | 6 | 2025 | 180 | 1.820 |
Why?
| | Stroke | 10 | 2025 | 1120 | 1.810 |
Why?
| | Coronary Artery Disease | 6 | 2023 | 698 | 1.740 |
Why?
| | Registries | 14 | 2025 | 2035 | 1.740 |
Why?
| | Medicare | 16 | 2025 | 773 | 1.720 |
Why?
| | Myocardial Infarction | 10 | 2025 | 1046 | 1.620 |
Why?
| | Aortic Valve | 7 | 2025 | 351 | 1.550 |
Why?
| | Treatment Outcome | 31 | 2025 | 10811 | 1.470 |
Why?
| | Data Accuracy | 3 | 2024 | 65 | 1.210 |
Why?
| | Risk Factors | 23 | 2025 | 10388 | 1.180 |
Why?
| | ST Elevation Myocardial Infarction | 4 | 2021 | 54 | 1.150 |
Why?
| | Platelet Aggregation Inhibitors | 7 | 2023 | 463 | 1.140 |
Why?
| | Insurance Claim Review | 2 | 2025 | 64 | 1.130 |
Why?
| | Patient Readmission | 7 | 2020 | 697 | 1.120 |
Why?
| | United States | 33 | 2025 | 14841 | 1.070 |
Why?
| | Postoperative Complications | 5 | 2025 | 2654 | 1.060 |
Why?
| | Directories as Topic | 2 | 2024 | 7 | 1.040 |
Why?
| | Insurance Carriers | 2 | 2024 | 11 | 1.030 |
Why?
| | Hospitals | 5 | 2023 | 691 | 1.020 |
Why?
| | Risk Assessment | 9 | 2025 | 3457 | 1.010 |
Why?
| | Hospital Mortality | 7 | 2024 | 911 | 1.000 |
Why?
| | Aged | 36 | 2025 | 23961 | 0.990 |
Why?
| | Aged, 80 and over | 18 | 2025 | 7635 | 0.930 |
Why?
| | Physicians | 2 | 2024 | 910 | 0.910 |
Why?
| | Endpoint Determination | 1 | 2025 | 77 | 0.890 |
Why?
| | Insurance, Health | 2 | 2024 | 283 | 0.870 |
Why?
| | Atherectomy, Coronary | 1 | 2023 | 10 | 0.850 |
Why?
| | Time Factors | 13 | 2025 | 6828 | 0.830 |
Why?
| | Heart Valve Prosthesis | 2 | 2021 | 114 | 0.810 |
Why?
| | Longevity | 1 | 2024 | 165 | 0.800 |
Why?
| | Shock, Cardiogenic | 1 | 2023 | 63 | 0.800 |
Why?
| | Mortality | 3 | 2018 | 362 | 0.780 |
Why?
| | Intensive Care Units | 3 | 2025 | 827 | 0.780 |
Why?
| | Postoperative Hemorrhage | 2 | 2021 | 86 | 0.780 |
Why?
| | Coronary Occlusion | 1 | 2022 | 19 | 0.760 |
Why?
| | Frailty | 2 | 2023 | 170 | 0.760 |
Why?
| | Humans | 63 | 2025 | 137585 | 0.760 |
Why?
| | Surgical Procedures, Operative | 1 | 2025 | 259 | 0.760 |
Why?
| | Vascular Calcification | 1 | 2023 | 108 | 0.750 |
Why?
| | Diabetes Mellitus | 3 | 2015 | 1040 | 0.740 |
Why?
| | Patient Discharge | 5 | 2024 | 897 | 0.720 |
Why?
| | Preventive Health Services | 2 | 2013 | 148 | 0.700 |
Why?
| | Anticoagulants | 3 | 2021 | 664 | 0.690 |
Why?
| | Mitral Valve | 2 | 2021 | 88 | 0.670 |
Why?
| | Clinical Trials as Topic | 4 | 2023 | 1050 | 0.650 |
Why?
| | Data Collection | 1 | 2023 | 673 | 0.650 |
Why?
| | Anesthesia, General | 1 | 2020 | 77 | 0.630 |
Why?
| | Severity of Illness Index | 2 | 2025 | 2828 | 0.630 |
Why?
| | Endovascular Procedures | 1 | 2023 | 312 | 0.630 |
Why?
| | Databases, Factual | 6 | 2025 | 1357 | 0.630 |
Why?
| | Data Mining | 1 | 2020 | 116 | 0.620 |
Why?
| | Conscious Sedation | 1 | 2020 | 92 | 0.620 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 322 | 0.600 |
Why?
| | Incidence | 8 | 2025 | 2804 | 0.580 |
Why?
| | Economics, Hospital | 1 | 2018 | 25 | 0.570 |
Why?
| | Students, Medical | 2 | 2013 | 348 | 0.570 |
Why?
| | Kidney Transplantation | 2 | 2015 | 708 | 0.560 |
Why?
| | Betacoronavirus | 1 | 2020 | 270 | 0.550 |
Why?
| | Peripheral Arterial Disease | 2 | 2023 | 475 | 0.550 |
Why?
| | Stents | 2 | 2021 | 527 | 0.540 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2018 | 99 | 0.540 |
Why?
| | Practice Patterns, Physicians' | 3 | 2021 | 1313 | 0.540 |
Why?
| | Occupational Exposure | 1 | 2020 | 341 | 0.520 |
Why?
| | Quality of Health Care | 3 | 2016 | 642 | 0.520 |
Why?
| | Male | 34 | 2025 | 67762 | 0.520 |
Why?
| | Retrospective Studies | 12 | 2025 | 15657 | 0.490 |
Why?
| | Coronary Angiography | 3 | 2023 | 317 | 0.490 |
Why?
| | Female | 33 | 2025 | 73304 | 0.480 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 373 | 0.480 |
Why?
| | Coronavirus Infections | 1 | 2020 | 364 | 0.480 |
Why?
| | Academic Medical Centers | 2 | 2015 | 512 | 0.460 |
Why?
| | Pneumonia | 2 | 2018 | 639 | 0.450 |
Why?
| | Angina Pectoris | 3 | 2022 | 65 | 0.450 |
Why?
| | Seasons | 1 | 2017 | 547 | 0.450 |
Why?
| | Health Personnel | 1 | 2020 | 710 | 0.430 |
Why?
| | Healthcare Disparities | 1 | 2020 | 654 | 0.420 |
Why?
| | Waiting Lists | 1 | 2015 | 266 | 0.410 |
Why?
| | Delayed Graft Function | 1 | 2013 | 33 | 0.400 |
Why?
| | Graft Survival | 1 | 2015 | 535 | 0.400 |
Why?
| | Intracranial Embolism | 2 | 2024 | 32 | 0.400 |
Why?
| | Tissue Donors | 1 | 2015 | 425 | 0.390 |
Why?
| | Income | 2 | 2022 | 202 | 0.380 |
Why?
| | Middle Aged | 18 | 2025 | 33479 | 0.380 |
Why?
| | Ambulatory Care Facilities | 1 | 2013 | 232 | 0.370 |
Why?
| | Community Health Centers | 1 | 2012 | 60 | 0.370 |
Why?
| | Tissue and Organ Procurement | 1 | 2015 | 321 | 0.360 |
Why?
| | Hospitalization | 4 | 2020 | 2199 | 0.350 |
Why?
| | Predictive Value of Tests | 3 | 2025 | 2031 | 0.340 |
Why?
| | Urban Renewal | 1 | 2010 | 5 | 0.340 |
Why?
| | Disease Management | 1 | 2015 | 628 | 0.340 |
Why?
| | Ambulatory Care | 1 | 2015 | 546 | 0.340 |
Why?
| | Poverty Areas | 1 | 2010 | 39 | 0.340 |
Why?
| | Odds Ratio | 5 | 2021 | 1070 | 0.330 |
Why?
| | Urban Health | 1 | 2010 | 92 | 0.330 |
Why?
| | Sanitation | 1 | 2010 | 55 | 0.320 |
Why?
| | Ischemic Attack, Transient | 2 | 2021 | 65 | 0.320 |
Why?
| | Water Supply | 1 | 2010 | 78 | 0.320 |
Why?
| | Communicable Disease Control | 1 | 2010 | 82 | 0.320 |
Why?
| | Quality Improvement | 2 | 2018 | 1178 | 0.310 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 140 | 0.310 |
Why?
| | Propensity Score | 4 | 2025 | 294 | 0.270 |
Why?
| | Sex Characteristics | 2 | 2014 | 762 | 0.270 |
Why?
| | Heart Failure | 2 | 2018 | 2236 | 0.270 |
Why?
| | Mass Screening | 2 | 2013 | 1287 | 0.260 |
Why?
| | Chronic Disease | 2 | 2023 | 1793 | 0.260 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3284 | 0.260 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 1477 | 0.260 |
Why?
| | Life Expectancy | 2 | 2016 | 69 | 0.250 |
Why?
| | Blood Glucose | 1 | 2015 | 2186 | 0.230 |
Why?
| | Fee-for-Service Plans | 1 | 2025 | 88 | 0.220 |
Why?
| | Medicare Part C | 1 | 2025 | 31 | 0.220 |
Why?
| | Drug Therapy, Combination | 3 | 2023 | 1066 | 0.220 |
Why?
| | Delivery of Health Care | 2 | 2018 | 951 | 0.220 |
Why?
| | Protective Factors | 1 | 2024 | 93 | 0.220 |
Why?
| | Limb Salvage | 1 | 2023 | 57 | 0.210 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2023 | 66 | 0.210 |
Why?
| | Community Health Services | 1 | 2025 | 227 | 0.210 |
Why?
| | Connecticut | 2 | 2014 | 27 | 0.210 |
Why?
| | Specialization | 1 | 2024 | 144 | 0.200 |
Why?
| | Primary Health Care | 1 | 2013 | 1738 | 0.200 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 5472 | 0.200 |
Why?
| | Chest Pain | 2 | 2020 | 91 | 0.200 |
Why?
| | Medicine | 1 | 2024 | 121 | 0.190 |
Why?
| | Disability Evaluation | 1 | 2024 | 290 | 0.190 |
Why?
| | Nitroglycerin | 1 | 2022 | 17 | 0.190 |
Why?
| | Echocardiography | 1 | 2025 | 642 | 0.190 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2025 | 261 | 0.190 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5131 | 0.190 |
Why?
| | Cardiovascular Diseases | 2 | 2025 | 2111 | 0.180 |
Why?
| | Coronary Stenosis | 1 | 2021 | 38 | 0.180 |
Why?
| | United States Department of Veterans Affairs | 1 | 2025 | 678 | 0.170 |
Why?
| | Glycyrrhiza | 1 | 2020 | 3 | 0.170 |
Why?
| | Glycyrrhetinic Acid | 1 | 2020 | 7 | 0.170 |
Why?
| | Mineralocorticoids | 1 | 2020 | 8 | 0.170 |
Why?
| | Hyperaldosteronism | 1 | 2020 | 8 | 0.170 |
Why?
| | Mitral Valve Insufficiency | 1 | 2021 | 68 | 0.170 |
Why?
| | Ischemia | 1 | 2023 | 409 | 0.170 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2020 | 6 | 0.170 |
Why?
| | Bioprosthesis | 1 | 2020 | 40 | 0.170 |
Why?
| | Cardiology Service, Hospital | 1 | 2020 | 24 | 0.160 |
Why?
| | Cardiologists | 1 | 2020 | 45 | 0.160 |
Why?
| | International Classification of Diseases | 1 | 2020 | 135 | 0.160 |
Why?
| | Sex Factors | 1 | 2025 | 2071 | 0.150 |
Why?
| | Drug Utilization | 1 | 2020 | 169 | 0.150 |
Why?
| | Death, Sudden, Cardiac | 1 | 2020 | 185 | 0.150 |
Why?
| | Thrombosis | 2 | 2020 | 371 | 0.150 |
Why?
| | Adult | 7 | 2023 | 37929 | 0.140 |
Why?
| | Risk | 1 | 2020 | 912 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2020 | 275 | 0.140 |
Why?
| | Health Services Research | 1 | 2020 | 404 | 0.140 |
Why?
| | Calcium | 1 | 2023 | 1199 | 0.140 |
Why?
| | New York | 1 | 2017 | 126 | 0.140 |
Why?
| | Quality Indicators, Health Care | 1 | 2020 | 307 | 0.130 |
Why?
| | Outpatients | 1 | 2020 | 396 | 0.130 |
Why?
| | Decision Support Techniques | 1 | 2020 | 421 | 0.130 |
Why?
| | Elective Surgical Procedures | 1 | 2017 | 179 | 0.120 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1587 | 0.120 |
Why?
| | Brain Ischemia | 1 | 2019 | 338 | 0.120 |
Why?
| | California | 1 | 2017 | 431 | 0.120 |
Why?
| | Young Adult | 5 | 2022 | 13209 | 0.120 |
Why?
| | Medicaid | 1 | 2020 | 435 | 0.120 |
Why?
| | Glycemic Index | 1 | 2015 | 27 | 0.120 |
Why?
| | Disease Progression | 1 | 2022 | 2757 | 0.110 |
Why?
| | Cold Ischemia | 1 | 2013 | 30 | 0.100 |
Why?
| | Venous Thromboembolism | 1 | 2016 | 316 | 0.100 |
Why?
| | Prognosis | 1 | 2021 | 4030 | 0.100 |
Why?
| | Physical Examination | 1 | 2013 | 241 | 0.100 |
Why?
| | Atrial Fibrillation | 1 | 2016 | 388 | 0.090 |
Why?
| | Egypt | 1 | 2011 | 11 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1639 | 0.090 |
Why?
| | Hemorrhage | 3 | 2023 | 722 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2016 | 556 | 0.090 |
Why?
| | Medically Uninsured | 1 | 2012 | 130 | 0.090 |
Why?
| | Linear Models | 1 | 2013 | 849 | 0.080 |
Why?
| | India | 1 | 2010 | 195 | 0.080 |
Why?
| | Policy Making | 1 | 2010 | 98 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2013 | 1509 | 0.080 |
Why?
| | Communicable Diseases | 1 | 2010 | 159 | 0.070 |
Why?
| | Regression Analysis | 1 | 2010 | 1024 | 0.070 |
Why?
| | Cardiac Catheterization | 2 | 2021 | 530 | 0.070 |
Why?
| | Aspirin | 2 | 2023 | 387 | 0.070 |
Why?
| | Health Policy | 1 | 2010 | 388 | 0.070 |
Why?
| | Comorbidity | 2 | 2025 | 1622 | 0.060 |
Why?
| | Logistic Models | 2 | 2021 | 2074 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2017 | 2531 | 0.050 |
Why?
| | Length of Stay | 2 | 2018 | 1215 | 0.050 |
Why?
| | Coronary Artery Bypass | 1 | 2023 | 234 | 0.050 |
Why?
| | Drug-Eluting Stents | 1 | 2021 | 81 | 0.040 |
Why?
| | Hypokalemia | 1 | 2020 | 24 | 0.040 |
Why?
| | Aldosterone | 1 | 2020 | 45 | 0.040 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2017 | 3715 | 0.040 |
Why?
| | Ventricular Fibrillation | 1 | 2020 | 60 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2022 | 266 | 0.040 |
Why?
| | Prasugrel Hydrochloride | 1 | 2020 | 22 | 0.040 |
Why?
| | Blood Chemical Analysis | 1 | 2020 | 99 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2020 | 303 | 0.040 |
Why?
| | Skilled Nursing Facilities | 1 | 2021 | 141 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2025 | 786 | 0.040 |
Why?
| | Cause of Death | 1 | 2021 | 434 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2020 | 565 | 0.040 |
Why?
| | Hydrocortisone | 1 | 2020 | 322 | 0.040 |
Why?
| | Electroencephalography | 1 | 2020 | 423 | 0.040 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2020 | 249 | 0.030 |
Why?
| | Algorithms | 1 | 2025 | 1704 | 0.030 |
Why?
| | Dabigatran | 1 | 2016 | 22 | 0.030 |
Why?
| | Child, Preschool | 2 | 2023 | 11074 | 0.030 |
Why?
| | Postoperative Period | 1 | 2017 | 342 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 816 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1483 | 0.030 |
Why?
| | Warfarin | 1 | 2016 | 154 | 0.030 |
Why?
| | Thrombolytic Therapy | 1 | 2016 | 142 | 0.030 |
Why?
| | Pyridones | 1 | 2016 | 168 | 0.030 |
Why?
| | Rivaroxaban | 1 | 2016 | 255 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2016 | 205 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 889 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2016 | 323 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1325 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2016 | 1266 | 0.030 |
Why?
| | Pyrazoles | 1 | 2016 | 423 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 3295 | 0.020 |
Why?
| | Adolescent | 2 | 2022 | 21513 | 0.020 |
Why?
| | Child | 2 | 2022 | 21935 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2691 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 6079 | 0.020 |
Why?
| | Infant | 1 | 2020 | 9465 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5778 | 0.010 |
Why?
|
|
Butala's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|